Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Wockhardt Ltd Q4FY24; 3% rise in Revenue
Categories
biopharma
Life Sciences Ltd Q2FY24; 25% fall in Revenue
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment
Sun Pharma Advanced Research Company Ltd Q2FY24; 34% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
Wockhardt Ltd Q1FY24; 8% rise in Revenue
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Suven Life Sciences Ltd Q1FY24; 0% equalled in Revenue
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment
Torrent Pharmaceuticals Ltd Q4FY23 revenue grows by 17%
Torrent Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹2,452 Crore, up from ₹ Crore year on year depicting a growth
Sun Pharma Advanced Research Company Q4FY23 results out, revenue grows by 92%
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. The company is
Syngene reported 21 percent rise in its Q4FY23 net profit
Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.While, consolidated
Syngene International Q4FY23 results out, revenue rises by 31%
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE : BIOCON) Q1 FY23 Earnings Concall dated July. 27, 2022 Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and
Biocon Limited (BIOCON) Q4 2022 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q4 2022 earnings concall dated Apr. 29, 2022 Corporate Participants: Aishwarya Seetharam -- Head, Investor Relations Kiran Mazumdar Shaw -- Executive Chairperson